The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 20, 2018

Filed:

Mar. 29, 2013
Applicant:

Opsona Therapeutics Limited, Dublin, IE;

Inventors:

Nils Kuklik, Essen, DE;

Wolf-Dieter Schubert, Bellville, ZA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); G01N 33/53 (2006.01); G01N 33/566 (2006.01); G01N 33/68 (2006.01); C07K 16/28 (2006.01); A61K 38/17 (2006.01); G06F 19/16 (2011.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70596 (2013.01); A61K 38/177 (2013.01); A61K 47/6849 (2017.08); C07K 14/705 (2013.01); C07K 16/2896 (2013.01); G01N 33/53 (2013.01); G06F 19/16 (2013.01); A61K 39/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2319/70 (2013.01); G01N 33/566 (2013.01); G01N 33/68 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70596 (2013.01);
Abstract

The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349, Leu371, Glu375, Tyr376 and His398 of TLR2 which define the identified epitope are provided for use in generating binding members. Also provided are binding members which bind to the identified epitope and methods of using same for the treatment and/or prevention of conditions associated with TLR2 activation and/or signalling.


Find Patent Forward Citations

Loading…